Navigation Links
AlphaRx Unveils its China Strategy
Date:7/21/2009

    AlphaRx plans to open an R&D facility and manufacturing plant in China
    with local partners, to introduce innovative drug products to the fastest
    growing pharmaceutical market in the world.

MARKHAM, ON, July 21 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company, utilizing proprietary drug delivery technology to develop novel formulations of drugs, is forging ahead with its growth strategy for Greater China. As part of this strategy, AlphaRx is poised to open a "state of the art" R D and pilot plant facility in China with local partners. The R D facility will focus on the development of innovative drug products targeting infectious disease and various forms of cancer. Additionally, the Company, together with its local partners, plans to develop adjuvant vaccines to treat influenza, such as H5N1 and H1N1 strains.

AlphaRx currently has a topical NSAID awaiting near-term registration in China and is developing a second product - GAI-122 - an injectable nanoemulsion, in collaboration with Gaia BioPharma for the treatment of acute hepatitis, a therapy with a multi-million dollar potential indication in China.

The Chinese government has been a strong supporter of the life sciences industry. It plans to further increase its investment in the sector through a variety of grants and awards in some of its leading science and technology parks and through the National Program 863, originally established in March 1983 by Deng Xiaoping to award grants to science and technology projects that have significant commercial value. Most notably, in November 2008, China launched the Mega New Drug Development Program, a plan to invest $10 billion over the next 13 years, with the aim of creating a China-based innovative drug development industry.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease
2. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
3. AlphaRx Shareholder Update
4. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
5. AlphaRx Signs Cooperative Research and Development Agreement with US Army
6. AlphaRx Provides Corporate and Development Update
7. AlphaRxs Indaflex(TM) Continues its Clinical Development
8. AlphaRx CEO Accumulates More Company Shares
9. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
10. AlphaRx Announces Debt Conversion
11. AlphaRx To Present at 47th Annual ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
(Date:9/19/2017)... LOUISVILLE, Ky. , Sept. 19, 2017   ZirMed ... and predictive analytics, today announced that it has been ranked ... the Black Book™ Rankings 2017 User Survey. ZirMed ... software solution for large hospitals and medical centers over 200 ... in Black Book,s healthcare technology user survey history. ...
Breaking Medicine Technology: